Abbott's Xience V beats Taxus in large-scale SPIRIT IV trial
This article was originally published in Clinica
Executive Summary
Abbott's market-leading drug-eluting stent (DES) Xience V has surpassed Taxus Express2, a rival device marketed by Boston Scientific, in a clinical trial.